公开(公告)号：US20240384002A1

公开(公告)日：2024-11-21

申请号：US18792966

申请日：2024-08-02

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley

IPC: C07K16/30 ,  A61K47/54 ,  A61K47/62 ,  A61K47/68 ,  C07K1/107

Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.

公开(公告)号：US12084475B2

公开(公告)日：2024-09-10

申请号：US17324150

申请日：2021-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley

IPC: C07K1/107 ,  A61K47/54 ,  A61K47/62 ,  A61K47/68

CPC classification number: C07K1/1077 ,  A61K47/549 ,  A61K47/62 ,  A61K47/68 ,  C07K2317/41 ,  C07K2319/30 ,  C07K2319/91

Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.

公开(公告)号：US20210388085A1

公开(公告)日：2021-12-16

申请号：US17324148

申请日：2021-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley ,  Rebecca Wissner

IPC: C07K16/28 ,  A61K47/68 ,  C12N9/10

Abstract: Engineered antibodies useful for site-specific conjugation by a transglutaminase are described. Also described are methods of site-specific conjugation of the antibodies, the site-specifically conjugated antibodies, and pharmaceutical compositions and uses related to the site-specifically conjugated antibodies.

公开(公告)号：US20240391849A1

公开(公告)日：2024-11-28

申请号：US18736405

申请日：2024-06-06

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: C07B59/00 ,  A61K39/00 ,  A61K51/10 ,  A61P35/00 ,  C07K16/30

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US20210017099A1

公开(公告)日：2021-01-21

申请号：US16955094

申请日：2018-12-17

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: C07B59/00 ,  C07K16/30 ,  A61K51/10 ,  A61P35/00

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US12227593B2

公开(公告)日：2025-02-18

申请号：US17324148

申请日：2021-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley ,  Rebecca Wissner

IPC: C07K16/32 ,  A61K47/68 ,  C07K16/28 ,  C12N9/10

Abstract: Engineered antibodies useful for site-specific conjugation by a transglutaminase are described. Also described are methods of site-specific conjugation of the antibodies, the site-specifically conjugated antibodies, and pharmaceutical compositions and uses related to the site-specifically conjugated antibodies.

公开(公告)号：US11576986B2

公开(公告)日：2023-02-14

申请号：US16869771

申请日：2020-05-08

Applicant: Janssen Biotech, Inc.

Inventor： Rhys Salter ,  Vadim Dudkin ,  Fengbin Song ,  Wei Zhang ,  Shalom Goldberg ,  John Keith

IPC: A61K51/02 ,  A61K51/04 ,  A61K51/10

Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

公开(公告)号：US20210363177A1

公开(公告)日：2021-11-25

申请号：US17324150

申请日：2021-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Michael J. McCauley ,  Kristen Wiley

IPC: C07K1/107 ,  A61K47/68 ,  A61K47/54 ,  A61K47/62

Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.

公开(公告)号：US20190184028A1

公开(公告)日：2019-06-20

申请号：US16218990

申请日：2018-12-13

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Andrew Elias ,  Shalom Goldberg ,  Donna Klein ,  Elise Kuhar ,  Tricia Lin ,  Lavanya Peddada ,  Karyn O'Neil ,  Kristen Wiley

IPC: A61K47/68 ,  A61P35/00 ,  C07K14/78 ,  A61P37/06 ,  B82Y5/00 ,  A61K47/69 ,  A61K47/64 ,  A61K47/42 ,  A61K31/7105

CPC classification number: A61K47/6807 ,  A61K31/7105 ,  A61K47/42 ,  A61K47/6415 ,  A61K47/6925 ,  A61K47/6929 ,  A61P35/00 ,  A61P37/06 ,  B82Y5/00 ,  C07K14/78

Abstract: A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications.